Results 171 to 180 of about 5,337 (191)

AMDA Position Statement on Aducanumab

Journal of the American Medical Directors Association, 2021
Lea C, Watson, Richard, Juman
openaire   +2 more sources

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

journal of prevention of Alzheimer's disease, The, 2022
Oskar Hansson, Frederik Barkhof, P S Aisen   +2 more
exaly  

Aducanumab/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Neurotherapeutics, 2022
Lars Lannfelt, Malin Johannesson, Christer Möller   +2 more
exaly  

The Problem of Aducanumab for the Treatment of Alzheimer Disease

Annals of Internal Medicine, 2021
G. Caleb Alexander, Jason Karlawish
openaire   +2 more sources

Aducanumab: look before leaping

Nature Medicine, 2021
openaire   +2 more sources

Ventricular enlargement caused by aducanumab

Nature Reviews Neurology, 2022
openaire   +2 more sources

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

International Journal of Molecular Sciences, 2022
Emanuela Mazzon, Serena Silvestro, Andrea Valeri   +2 more
exaly  

Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease

Recent Patents on Biotechnology, 2022
Mohammad Saeedi, Fatemeh Mehranfar
exaly  

Thinking beyond the Aducanumab Controversy

Annals of Neurology, 2021
openaire   +2 more sources